Who are Rasagiline mesylate plus Mirapex's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rasagiline-mesylate-plus-mirapex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Rasagiline mesylate plus Mirapex — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rasagiline mesylate plus Mirapex (Rasagiline mesylate plus Mirapex) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MAO-B inhibitor plus dopamine agonist combination. Area: Neurology.

marketed MAO-B inhibitor plus dopamine agonist combination Monoamine oxidase B and dopamine D2/D3 receptors Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Rasagiline mesylate plus Mirapex (Rasagiline mesylate plus Mirapex) — Teva Neuroscience, Inc.. This combination pairs a monoamine oxidase B inhibitor with a dopamine agonist to enhance dopaminergic signaling in the brain for Parkinson's disease management.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rasagiline mesylate plus Mirapex TARGET	Rasagiline mesylate plus Mirapex	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor plus dopamine agonist combination	Monoamine oxidase B and dopamine D2/D3 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MAO-B inhibitor plus dopamine agonist combination class)

Teva Neuroscience, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rasagiline mesylate plus Mirapex — Competitive Intelligence Brief. https://druglandscape.com/ci/rasagiline-mesylate-plus-mirapex. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab